ArticleEndocrine pathology2015
Novel BRAF and KRAS Mutations in Papillary Thyroid Carcinoma Arising in Struma Ovarii.
Article in Endocrine pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Surgical approach and recurrence risk in struma ovarii: A retrospective and systematic analysis.Biomolecules & biomedicine · 2025Pooled it
- Malignant struma ovarii: clinicopathological and molecular features in a series of nine cases.Virchows Archiv : an international journal of pathology · 2026Article
- Malignant Struma Ovarii: A Rare Manifestation of Ectopic Thyroid Cancer.JCEM case reports · 2025Article
- Relationship Between Thyroid Dysfunction and Ovarian Cancer.Biomolecules · 2025Review
- Case Report: Strumal carcinoid tumor in the ovary: report of a rare occurrence with a review of literature.Frontiers in medicine · 2025Article
- Papillary Thyroid Carcinoma Arising Within a Mature Ovarian Cystic Teratoma: A Case Report.Case reports in endocrinology · 2025Article
- Hyperthyroidism in thyroid carcinoma originating in struma ovarii.Endocrinology, diabetes & metabolism case reports · 2024Article
- Identification of GermlineInternational journal of molecular sciences · 2024Article
- Identifying the Carcinogenic Mechanism of Malignant Struma Ovarii Using Whole-Exome Sequencing and DNA Methylation Analysis.Current issues in molecular biology · 2023Article
- Integrated proteogenomic characterization of medullary thyroid carcinoma.Cell discovery · 2022Article
- Management of malignant struma ovarii: is aggressive therapy justified? Case report and literature review.Thyroid research · 2022Article
- Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary.BMC cancer · 2021Article
- Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations.Endocrine · 2021Article
- FIGO Stage IV and Age Over 55 Years as Prognostic Predicators in Patients With Metastatic Malignant Struma Ovarii.Frontiers in oncology · 2020Article
- Malignant struma ovarii presenting with follicular carcinoma: A case report with molecular analysis.Gynecologic oncology reports · 2019Article
- Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature.Case reports in endocrinology · 2019Article
- Synchronous Independent Papillary Thyroid Carcinomas in Struma Ovarii and the Thyroid Gland With DifferentJournal of the Endocrine Society · 2018Article
- miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.Oncology reports · 2017Article
- Struma ovarii with unique histological features: a case report.International journal of clinical and experimental pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary carcinomas of thyroid type rarely arise within struma ovarii. There are limited data on the immunohistochemical and molecular features of these tumors. Three cases of papillary carcinoma arising in struma ovarii (PCSO) were identified. The clinicopathological features were reviewed and immunohistochemical staining for HBME-1, cytokeratin (CK) 19, and CD56 was performed. Tumor DNA was sequenced for somatic mutations using a panel of 26 oncogenes, with a particular focus on BRAF and KRAS mutations. The patients were aged 22, 48, and 55 years. All cases were FIGO stage IA. Two tumors were of classical histological type, and one was a follicular variant papillary carcinoma. All tumors expressed HBME-1 and two were positive for CK19. CD56 was negative in all three cases. One tumor demonstrated a BRAF G469A mutation in exon 11, and in a second case, a KRAS Q61K double base mutation in exon 3 was detected. These mutations have not been described previously in PCSO. No mutations were detected in the benign follicular components of the tumors adjacent to the malignant papillary tissue. None of the patients had tumor recurrence on clinical follow-up (range 11 months to 8½ years). HBME-1, CK19, and CD56 are useful immunohistochemical markers of PCSO. Novel BRAF and KRAS mutations were identified in two of three tumors suggesting that mutations in PCSO may differ from those commonly identified in papillary carcinoma of the eutopic thyroid. The clinical significance of these mutations is uncertain but follow-up data in this small series support the generally good prognosis of PCSO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.